- Home
- ASRT vs RVPH Comparison
ASRT vs RVPH Comparison
Compare ASRT & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASRT
- RVPH
- Stock Information
- Founded
- ASRT 1995
- RVPH 2006
- Country
- ASRT United States
- RVPH United States
- Employees
- ASRT N/A
- RVPH N/A
- Industry
- ASRT Biotechnology: Pharmaceutical Preparations
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- ASRT Health Care
- RVPH Health Care
- Exchange
- ASRT Nasdaq
- RVPH Nasdaq
- Market Cap
- ASRT 85.1M
- RVPH 88.0M
- IPO Year
- ASRT 1997
- RVPH N/A
- Fundamental
- Price
- ASRT $0.83
- RVPH $1.98
- Analyst Decision
- ASRT Strong Buy
- RVPH Strong Buy
- Analyst Count
- ASRT 4
- RVPH 5
- Target Price
- ASRT $3.19
- RVPH $11.40
- AVG Volume (30 Days)
- ASRT 419.9K
- RVPH 2.2M
- Earning Date
- ASRT 03-10-2025
- RVPH 11-14-2024
- Dividend Yield
- ASRT N/A
- RVPH N/A
- EPS Growth
- ASRT N/A
- RVPH N/A
- EPS
- ASRT N/A
- RVPH N/A
- Revenue
- ASRT $125,763,000.00
- RVPH N/A
- Revenue This Year
- ASRT N/A
- RVPH N/A
- Revenue Next Year
- ASRT $1.84
- RVPH N/A
- P/E Ratio
- ASRT N/A
- RVPH N/A
- Revenue Growth
- ASRT N/A
- RVPH N/A
- 52 Week Low
- ASRT $0.73
- RVPH $0.60
- 52 Week High
- ASRT $1.80
- RVPH $4.83
- Technical
- Relative Strength Index (RSI)
- ASRT 45.42
- RVPH 56.56
- Support Level
- ASRT $0.78
- RVPH $1.78
- Resistance Level
- ASRT $0.85
- RVPH $1.91
- Average True Range (ATR)
- ASRT 0.03
- RVPH 0.18
- MACD
- ASRT 0.00
- RVPH -0.00
- Stochastic Oscillator
- ASRT 56.14
- RVPH 86.00
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.